-ai.png)
Developing a promising medical innovation into a clinically applicable product often requires overcoming significant technical and scientific challenges. While early-stage research may establish a concept's potential, additional evidence is frequently needed before researchers can secure larger translational funding or attract commercial investment.
The Medical Research Council (MRC) Impact Acceleration Awards, delivered through UK Research and Innovation (UKRI), aim to bridge this gap by supporting focused, high-risk development activities.
The programme provides funding for academically led projects developing new or repurposed medicines, medical devices, diagnostics and other medical interventions. Rather than supporting extensive development programmes, the awards focus on a single critical step that could substantially improve an innovation's prospects for further development.
Previously known as the Gap Fund: Single-Step Support for Medical Product Development, the programme sits between smaller MRC Impact Acceleration Account awards and larger MRC Proof of Concept funding opportunities.
Key Dates and Funding
Opens: 16 July 2026, 09:00 UK time
Closes: 11 November 2026, 16:00 UK time
Funding: £50,000 to £300,000 in full economic project costs
Funding Rate: 80% of full economic costs, with 100% funding for permitted exceptions
Project Duration: 6 to 18 months
Applicants should request only the funding necessary to address their proposed development challenge. Requests for the maximum amount must be scientifically justified.
What Does the Programme Support?
The Impact Acceleration Awards support translational research projects that have already established an initial concept and generated preliminary evidence supporting its potential.
The programme is intended to help researchers overcome a single high-risk development barrier that currently prevents the innovation from progressing towards more substantial funding or clinical application.
Projects should demonstrate how addressing this barrier will generate the critical evidence needed to inform further development decisions.
The programme supports innovations addressing a wide range of human diseases and medical conditions, including those relevant to UK healthcare and global health.
Its strategic priorities include:
Eligible Technologies and Innovations
The programme supports a broad range of medical products and interventions.
Medicines and Advanced Therapeutics
Eligible innovations include new small-molecule medicines, vaccines, biologics, antibodies, peptides, proteins and advanced therapeutic approaches.
Projects involving gene therapies, cell therapies, RNA therapies, nucleic acid therapies, regenerative medicine and complex medicines such as antibody-drug conjugates may also be supported.
Importantly, the programme also supports drug repurposing, including the investigation of existing medicines for new therapeutic indications.
Medical Devices and Diagnostics
Funding can support the development of medical devices, diagnostic technologies, medical imaging systems and surgical tools.
Relevant activities may include early prototype testing, high-risk prototype development and initial biomarker validation.
However, the programme supports biomarker validation rather than initial biomarker identification, reflecting its focus on translational development rather than exploratory discovery research.
Digital Health and AI Technologies
Digital healthcare technologies, medical applications and AI-enabled medical innovations are also eligible.
Where artificial intelligence is central to the proposed technology, applicants must provide a clear justification for the available data, proposed methodology, relevant expertise and measurable success criteria.
Projects may involve developing AI models using existing data, clinically validating models, repurposing existing models for new interventions or collecting new data to develop a model.
The Single-Step Development Requirement
One of the most important features of this funding opportunity is its emphasis on a single, clearly defined development challenge.
Unlike larger translational research grants, the Impact Acceleration Awards are not designed to fund projects containing multiple development stages or extensive work packages.
Instead, applicants must identify one critical technical or scientific uncertainty and demonstrate how the proposed activities will resolve it.
Examples of potentially eligible activities include:
The proposed project should generate a clear outcome that allows researchers to determine whether the innovation is ready for further development or whether the approach should be discontinued.
A technically unsuccessful outcome can still be valuable if it provides sufficient evidence to make an informed development decision.
Who Can Apply?
The programme is open to researchers based at MRC-eligible research organisations.
Applicants must demonstrate that they will actively direct and participate in the proposed project.
Eligible project leads may include researchers working at approved UK universities and research organisations.
Businesses and charity or third-sector organisations that are not approved UKRI Independent Research Organisations cannot normally act as project leads or co-leads. However, they may participate as project partners in applications led by eligible research organisations.
Approved UKRI Independent Research Organisations may apply where they meet the relevant eligibility requirements.
Why This Opportunity Matters
Promising medical innovations often encounter a funding gap between early scientific discovery and the evidence required to secure substantial translational investment.
The MRC Impact Acceleration Awards address this challenge by supporting targeted development activities that could significantly improve an innovation's prospects for further progression.
For academic researchers and research-led healthcare innovators, the programme provides an opportunity to generate critical evidence, strengthen intellectual property and establish a clearer development pathway.
By focusing on a single high-risk step, the funding can help researchers make informed decisions about whether to advance an innovation towards larger programmes such as the MRC Proof of Concept funding opportunity, industry collaboration or eventual clinical application.
How Inventya Can Help
A competitive MRC Impact Acceleration Award application must demonstrate a strong scientific rationale, a clearly defined high-risk development step and a credible pathway towards future clinical or commercial impact. Applicants need to show how the proposed work will generate the specific evidence required to unlock further development opportunities.
Our support can include:
Inventya's experience in healthcare innovation, translational research funding and commercialisation strategy can help applicants develop a focused, evidence-driven proposal that demonstrates how overcoming one critical development barrier could unlock the next stage of medical innovation.
